Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-25
DOI
10.3389/fimmu.2020.00331
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
- (2017) Abhishek D. Garg et al. IMMUNOLOGICAL REVIEWS
- Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation
- (2017) Shuhei Hosomi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer
- (2015) Tomoharu Miyashita et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Combinatorial Strategies for the Induction of Immunogenic Cell Death
- (2015) Lucillia Bezu et al. Frontiers in Immunology
- DAMPs from Cell Death to New Life
- (2015) Emilie Vénéreau et al. Frontiers in Immunology
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- High hydrostatic pressure induces immunogenic cell death in human tumor cells
- (2014) Jitka Fucikova et al. INTERNATIONAL JOURNAL OF CANCER
- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
- (2013) Abhishek D. Garg et al. BIOFACTORS
- Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
- (2013) Tomar Ghansah et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
- (2013) H Inoue et al. CELL DEATH AND DIFFERENTIATION
- NK cell-based immunotherapy for malignant diseases
- (2013) Min Cheng et al. Cellular & Molecular Immunology
- Immunogenic Tumor Cell Death Induced by Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
- (2012) Yoshiyuki Suzuki et al. CANCER RESEARCH
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
- (2012) Abhishek D Garg et al. EMBO JOURNAL
- 5-Fluorouracil and Interferon-α Immunochemotherapy Enhances Immunogenicity of Murine Pancreatic Cancer Through Upregulation of NKG2D Ligands and MHC Class I
- (2012) Hadeel Khallouf et al. JOURNAL OF IMMUNOTHERAPY
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
- (2012) L. Menger et al. Science Translational Medicine
- Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
- (2011) J. Fucikova et al. CANCER RESEARCH
- CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells
- (2011) Zhangguo Chen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown
- (2011) Abhishek D. Garg et al. PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Targeting the Immune System in Cancer
- (2009) Devyani Chaudhuri et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- NKG2D ligands in tumor immunity
- (2008) N Nausch et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started